v3.26.1
CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - USD ($)
Mar. 31, 2026
Mar. 31, 2025
Current assets:    
Cash $ 6,438,909 $ 4,228,944
VAT receivable 27,112 30,654
Inventories 0 94,675
Prepaid expenses and deposits 362,577 539,382
Total current assets 6,828,598 4,893,655
Non-current assets    
Right-of-use assets, net 327,381 306,652
Property, plant & equipment, net 1,168,793 1,226,596
Total non-current assets 1,496,174 1,533,248
Total assets 8,324,772 6,426,903
Current liabilities:    
Accounts payable and accrued liabilities 309,463 250,170
Lease liabilities, current 81,102 52,993
Accounts payable - related parties 265,982 337,576
Loan payable 28,477 32,468
Total current liabilities 685,024 673,207
Non-current liabilities:    
Non-current lease liabilities 304,808 291,543
Total liabilities 989,832 964,750
Commitment and contingencies (Note 15)
Virax Biolabs Shareholders' equity    
Ordinary shares, $0.01 par value, 2,000,000 shares authorized; 579,218 and 173,679 issued and outstanding as of March 31, 2026 and 2025, respectively 14,480 4,342
Reserves 37,486,133 30,168,692
Accumulated deficit (29,612,994) (24,589,244)
Accumulated Other Comprehensive Income (loss) (310,278) 112,330
Total shareholders' equity (Virax Biolabs) 7,577,341 5,696,120
Non-controlling interests (242,401) (233,967)
Total shareholders' equity attributable to Virax Biolabs ordinary shareholders 7,334,940 5,462,153
Total liabilities and shareholders' equity $ 8,324,772 $ 6,426,903